{"id":"W4283328755","doi":"10.1097/01.hs9.0000847280.69256.81","title":"P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Rituximab; Lenalidomide; Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Phases of clinical research; Oncology; CD20; Gastroenterology; Clinical trial; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006383764,0.0008220146,0.001990666,0.0002486434,0.0007070804,0.00008919885,0.0002770859,0.0002287562,0.0005844633],"category_scores_gemma":[0.0002446034,0.0007005427,0.0003502058,0.0004645502,0.0002381517,0.0002739231,0.0004752844,0.0001991607,0.00001727753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001831688,"about_ca_system_score_gemma":0.001115385,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001244276,"about_ca_topic_score_gemma":0.0004899967,"domain_scores_codex":[0.9953779,0.0003019114,0.001082716,0.001298139,0.001064885,0.0008744643],"domain_scores_gemma":[0.9967301,0.001014659,0.0005629463,0.0009437788,0.0002121401,0.0005363575],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.655809,0.1193892,0.007490213,0.002597974,0.007718151,0.01191304,0.01253665,0.0001275438,0.001931996,0.001021455,0.01297624,0.1664885],"study_design_scores_gemma":[0.9180947,0.02070591,0.003651556,0.0003269646,0.003194107,0.001675028,0.01971772,0.00165057,0.002962127,0.00005561401,0.02700642,0.0009592703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845473,0.009047923,0.0001041166,0.0004326598,0.0004298289,0.004517418,0.0003451887,0.0001216057,0.0004539313],"genre_scores_gemma":[0.9934293,0.0003405007,0.001504044,0.0002559332,0.0002175588,0.002471167,0.0001671074,0.0001519842,0.001462431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2622856,"threshold_uncertainty_score":0.9995446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03182701236345815,"score_gpt":0.3023487328686932,"score_spread":0.270521720505235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}